Leak of ambassador's memos about Trump could harm UK-U.S. relations: British minister

Reuters | July 08, 2019

Leak of ambassador's memos about Trump could harm UK-U.S. relations: British minister
The leak of confidential memos from Britain is ambassador to the United States in which he describes President Donald Trump is administration as dysfunctional and inept could damage relations, a British minister said on Monday. Trade Minister Liam Fox, who is on a visit to Washington, said he would apologise to the president is daughter Ivanka Trump who he is due to meet during his trip.

Spotlight

Congress and FDA have worked hard to make sure that the drug approval process—the final stage of drug development—provides Americans with the earliest possible access to safe and effective drugs. As a result, since 2001, FDA’s approval process has become the fastest overall in the world, and Americans have had first access to new drugs more often than anywhere else in the world.1 And, over the last 50 years, the growth of modern science has stimulated the development of drugs for a wide variety of diseases that were previously untreatable.

Related News

GOVERNMENT BUSINESS

Endo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims

Endo | December 24, 2021

Endo International plc today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Texas. The settlement, which is subject to certain conditions and contingencies, provides a framework through which Endo and its subsidiaries can fully and finally resolve the opioid-related claims of Texas and its subdivisions in exchange for a total payment of $63 million. The settlement includes no admission of wrongdoing, fault or liability of any kind by Endo or its subsidiaries, and the settlement value should not be extrapolated to any other opioid-related cases or claims. The Texas settlement resolves, among other things, claims against Endo's subsidiaries in two cases set for trial in Texas state court in 2022: County of Dallas v. Purdue Pharma, L.P., et al., Texas MDL Pretrial Cause No. 2018-77098, and County of Bexar v. Purdue Pharma, L.P., et al., Texas MDL Pretrial Cause No. 2018-77066. The plaintiffs in those cases agreed to sever Endo's subsidiaries from these upcoming trials pending implementation of the settlement. The Company is continuing to litigate opioid claims not covered by its settlements and to pursue settlements that it believes are in its best interests while remaining focused on its primary goal of achieving a global settlement. At the same time, Endo is exploring other strategic alternatives, and may seek to implement one or more of those alternatives in the event it is unable to achieve a global settlement. Endo cannot speculate on the likelihood, nature or timing of any outcome. About Endo International plc Endo is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them.

Read More

GOVERNMENT BUSINESS

George Mason's Center for Business Civic Engagement and UiPath Launches Robotic Process Automation Initiative

UiPath | January 12, 2021

The Center for Business Civic Engagement (CBCE) at George Mason University (Mason) declared today the foundation of the Robotic Process Automation (RPA) Initiative in association with driving endeavor RPA programming organization UiPath to decide the effect of RPA on government viability and effectiveness. The mission of the RPA Initiative is to explore, instruct, and impart how the reception of this arising innovation can improve efficiency, activities, and administration conveyance of public area associations. The RPA Initiative will likewise examine and suggest conceivable administration models and public arrangement activities for RPA sending with regards to the more extensive financial standpoint and the eventual fate of work. “We are excited to partner with UiPath, a leader and innovator, and look forward to helping determine how RPA usage can improve the working of public sector organizations and succeed in meeting the ever-growing demand for services among stakeholders,” said Dr. David K. Rehr, Director of the Center and a faculty member at the Schar School of Policy and Government at Mason. “The RPA industry has risen to the occasion to help combat the COVID-19 pandemic through civic engagement. This is a critical endeavor and timely moment in our history.” “Mason has a history of innovation, technology, and studying public policy. We believe the partnership is a great fit and will benefit citizens seeking greater value in public sector programs and initiatives,” said Bobby Patrick, UiPath CMO. “Our Center at Mason focuses on researching ways to make government more effective and efficient. We have seen recent examples of RPA deployments throughout federal, local, and state governments helping to confront the COVID pandemic while protecting the safety of our citizens,” continued Rehr. These mission-empowering advancements offer extraordinary assistance in making government programs more effective and delivery government representatives from dull, everyday work, permitting them to be more innovative and inventive in this new typical. About the Center for Business Civic Engagement at George Mason University (GMU) The mission of the Center for Business Civic Engagement is to study the impact of the application of business theory and principles to government to determine if government can be both more effective and efficient for its stakeholders. About UiPath UiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.

Read More

GOVERNMENT BUSINESS

Deloitte Launches Artificial Intelligence Institute for Government

Deloitte | March 17, 2021

Deloitte's administration and public administrations practice announced the new Deloitte Artificial Intelligence Institute for Government today. Institute pioneers illustrated a bunch of commitments and activities to progress applied AI in the public area by building a cross-area local area for research and shared mastery, and tutoring and developing the talent of things to come. "As evidenced in the recent National Security Commission on Artificial Intelligence report, advancing the use of artificial intelligence is a national imperative. While decisions and actions to accelerate AI innovation need to happen today, implementing AI brings ethical and technical challenges that are as complex as any we have faced in recent history," said Ed Van Buren, principal with Deloitte Consulting LLP and executive director of DAIIG. "Deloitte's AI Institute for Government is focused on efforts to actively help the public sector harness and shape this movement towards blending human and machine capabilities in a way that improves citizen services, promotes economic growth and recovery, and expands human opportunity" The institute is a center for imaginative viewpoints, coordinated effort and examination zeroed in on everything AI and related innovations for government. To accomplish this, the institute will draw in pioneers from state, neighborhood and national government, industry, and the scholarly world. The people group will reach past technologists to remember disciplines for the humanities and sciences. "AI is more than technology — its adoption presents a seismic shift in the future of how work is done and how public servants, individuals and society work with intelligent machines and big data," said Tasha Austin, principal with Deloitte Risk & Financial Advisory, Deloitte & Touche LLP; and director of DAIIG. "The community built through this institute is at the leading edge of how AI is applied to the work of government to improve everything from health care to national defense. We will address critical questions of how we build ethics and transparency into the very DNA of AI to foster trust and advance human potential, rather than increase inequity." Some of the work and commitments underway for DAIIG's first year are listed below. Build an AI community of research and shared expertise The talent and capabilities embodied in the institute convey applied AI contextual analyses that make solid contrasts in open area challenges. The institute is a middle for AI in the public area local area and cultivates learning, investigation and a trade of thoughts. Early commitments include: • Research and develop AI-powered solutions in collaboration with https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/health-equity-institute.htmlDeloitte's AI Exploration Lab at the Capital Factory in Austin, Texas and the newly launched CortexAI™ for Government platform. The lab is an innovation hub and storefront to sense new AI technologies, incubate capabilities and create a space for co-development and collaboration. The lab specializes in operational data science, edge computing and the intersection of national security and AI technology innovation. • Leverage industry leading AI experts from our government and public sector practice to research AI, develop solutions and publish insights to problems that matter to the government. • Support existing AI communities of practice in government through events co-sponsored with leading nonprofits and trade associations. • Establish relationships with academic institutions to identify trends and conduct interdisciplinary research on applied AI for the purpose of pioneering and creating disruptive AI technologies and solutions for the public sector. Mentor and grow AI talent of the future Establish a robust arrangement of partnerships with driving scholastic projects and advance individual coaching programs for early profession people, based on the central obligation to advance variety and incorporation in the field. Early activities include: • Lead a discussion of women leaders around AI and Success for Women in STEM careers at the virtual University of Virginia Women in Data Science Worldwide Conference on Friday, March 19. • Provide mentorship opportunities and resources such as scholarships for rising STEM students from underrepresented communities and Historically Black Colleges and Universities (HBCUs). • Collaborate with United Way of the National Capital Area to bring AI concepts and technology to middle schoolers in the Greater Washington Metro Area. Deloitte's administration and public administrations practice — our kin, thoughts, innovation and results — is intended for sway. Deloitte's group of more than 16,000 experts carry new viewpoint to assist customers with expecting interruption, reconsider the conceivable, and satisfy their main goal guarantee. About Deloitte Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500® and more than 7,000 private companies. Our people come together for the greater good and work across the industry sectors that drive and shape today's marketplace — delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthier society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Building on more than 175 years of service, our network of member firms spans more than 150 countries and territories.

Read More

Spotlight

Congress and FDA have worked hard to make sure that the drug approval process—the final stage of drug development—provides Americans with the earliest possible access to safe and effective drugs. As a result, since 2001, FDA’s approval process has become the fastest overall in the world, and Americans have had first access to new drugs more often than anywhere else in the world.1 And, over the last 50 years, the growth of modern science has stimulated the development of drugs for a wide variety of diseases that were previously untreatable.